Long‐term sustainability of glycaemic achievements with second‐line antidiabetic therapies in patients with type 2 diabetes: A real‐world study

To inform patients and their carers about both the probability of reducing glycated haemoglobin (HbA1c) to clinically desirable levels and the sustainability of such control over 2 years with major second‐line antidiabetic therapies, in individual risk scenarios, with and without third‐line intensification.

[1]  D. Giugliano,et al.  Comment on Edelman and Polonsky. Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control. Diabetes Care 2017;40:1425–1432 , 2018, Diabetes Care.

[2]  J. Shaw,et al.  Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes , 2017, Diabetes Care.

[3]  M. Boemi,et al.  Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. , 2017, The lancet. Diabetes & endocrinology.

[4]  W. Polonsky,et al.  Type 2 Diabetes in the Real World: The Elusive Nature of Glycemic Control , 2017, Diabetes Care.

[5]  W. Polonsky,et al.  Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes , 2017, Diabetes Care.

[6]  Ognjen Arandjelovic,et al.  Data Mining Approach to Estimate the Duration of Drug Therapy from Longitudinal Electronic Medical Records , 2017, The Open Bioinformatics Journal.

[7]  J. Garber,et al.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[8]  M. McCarthy,et al.  Painting a new picture of personalised medicine for diabetes , 2017, Diabetologia.

[9]  Standards of Medical Care in Diabetes—2017: Summary of Revisions , 2016, Diabetes Care.

[10]  K. Klein,et al.  Weight gain in insulin‐treated patients by body mass index category at treatment initiation: new evidence from real‐world data in patients with type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[11]  T. Gill,et al.  Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013 , 2016, Diabetes Care.

[12]  W. Rathmann,et al.  Change in glycated haemoglobin levels after initiating second‐line therapy in type 2 diabetes: a primary care database study , 2016, Diabetes, obesity & metabolism.

[13]  David W. Johnson,et al.  Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis. , 2016, JAMA.

[14]  S. Hutfless,et al.  Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes , 2016, Annals of Internal Medicine.

[15]  I. Idris,et al.  Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study , 2016, Annals of medicine.

[16]  L. Pedersen,et al.  Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes , 2015, Diabetologia.

[17]  R. Heine,et al.  Comment on Zhang et al. Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better? Diabetes Care 2014;37:1338–1345 , 2014, Diabetes Care.

[18]  N. Shah,et al.  Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better? , 2014, Diabetes Care.

[19]  Greg Ridgeway,et al.  Toolkit for Weighting and Analysis of Nonequivalent Groups , 2014 .

[20]  D. Nathan,et al.  Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) , 2013, Diabetes Care.

[21]  Nisa M. Maruthur,et al.  Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations , 2011, Annals of Internal Medicine.

[22]  M. Hamburg,et al.  Regulatory action on rosiglitazone by the U.S. Food and Drug Administration. , 2010, The New England journal of medicine.

[23]  Albert G Crawford,et al.  Comparison of GE Centricity Electronic Medical Record database and National Ambulatory Medical Care Survey findings on the prevalence of major conditions in the United States. , 2010, Population health management.

[24]  J. Tanne.  FDA places “black box” warning on antidiabetes drugs , 2007, BMJ : British Medical Journal.

[25]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[26]  C. Kirkness,et al.  Assessment of Cardiometabolic Risk Factors in a National Primary Care Electronic Health Record Database , 2007 .

[27]  H. Quan,et al.  Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative Data , 2005, Medical care.

[28]  D. McCaffrey,et al.  Propensity score estimation with boosted regression for evaluating causal effects in observational studies. , 2004, Psychological methods.

[29]  J. Lunceford,et al.  Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study , 2004, Statistics in medicine.

[30]  Rury R. Holman,et al.  Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .

[31]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.